PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-1.23%
Negative revenue growth while 3391.T stands at 4.27%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
4.03%
Gross profit growth above 1.5x 3391.T's 2.40%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
16.71%
EBIT growth below 50% of 3391.T's 134.26%. Michael Burry would suspect deeper competitive or cost structure issues.
10.30%
Operating income growth under 50% of 3391.T's 78.69%. Michael Burry would be concerned about deeper cost or sales issues.
4.09%
Net income growth under 50% of 3391.T's 98.80%. Michael Burry would suspect the firm is falling well behind a key competitor.
4.08%
EPS growth under 50% of 3391.T's 98.73%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
4.08%
Diluted EPS growth under 50% of 3391.T's 98.65%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.00%
Share reduction while 3391.T is at 0.06%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3391.T is at 0.14%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.09%
10Y revenue/share CAGR under 50% of 3391.T's 185.57%. Michael Burry would suspect a lasting competitive disadvantage.
71.44%
5Y revenue/share CAGR similar to 3391.T's 78.64%. Walter Schloss might see both companies benefiting from the same mid-term trends.
36.36%
3Y revenue/share CAGR at 75-90% of 3391.T's 42.91%. Bill Ackman would expect new product strategies to close the gap.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
155.81%
Net income/share CAGR at 50-75% of 3391.T's 272.98%. Martin Whitman might question if the firm’s product or cost base lags behind.
122.26%
5Y net income/share CAGR above 1.5x 3391.T's 53.92%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
61.49%
3Y net income/share CAGR above 1.5x 3391.T's 29.88%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
198.97%
10Y equity/share CAGR at 75-90% of 3391.T's 222.95%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
124.19%
5Y equity/share CAGR above 1.5x 3391.T's 72.78%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
57.00%
3Y equity/share CAGR 1.25-1.5x 3391.T's 41.02%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
-100.00%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Firm’s AR is declining while 3391.T shows 42.97%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.29%
Inventory shrinking or stable vs. 3391.T's 10.68%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-1.54%
Negative asset growth while 3391.T invests at 27.36%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
4.33%
75-90% of 3391.T's 5.34%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
-44.81%
We’re deleveraging while 3391.T stands at 300.22%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
89.49%
We expand SG&A while 3391.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.